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Making a decision to adopt or reject an intervention based on
the evidence driven from medical literature, requires a clear
understanding of the risk of adverse outcome and its relation
(association) to this intervention. For example to choose a par-
ticular anti-arrythemic drug therapy may be based on the rela-
tion of this drug in reducing the risk of mortality. Expressing
this concept might be done in several methods. Surprisingly,
these different methods for expressing the same fact may lead
to somewhat different understanding (and hence decisions) by
the health practitioners.
Assume that the mortality risk related to cardiac event in
diabetic patients of average normal weight above 60 years is
20% within 5 years. If this estimation becomes true then ined.sa, mahmoud_barbary@
versity. All rights reserved.
Saud University.
lseviereach 100 patients, 20 patients will die within 5 years. That
example introduced the ﬁrst term of risk which is the ‘‘event
rate’’ or ER.
Let us now consider in these patients a hypothetical con-
dition of overweight where each extra 1 kg above the aver-
age weight constitutes a cardiac hazard that leads to an
extra 1% increase in mortality (compared to the population
with normal weight) related to cardiac event. So if you have
a similar group in which each patient has an extra 100 kg
weight, this will increases their risk by 100% and their ex-
pected ER will be doubled to = 40% i.e., from 100 patients,
40 will die within 5 years. The patient new base line expected
risk is 40%.
Now, suppose that you are studying certain interventions
(like surgical procedure as gastric band versus diet control).
If the diet failed to make any weight loss, while gastric band
operation lead to loss of 25 kg in weight. There are several
methods that the patient can express this weight loss.
One may say
1. I Lost 25 kg. This is my absolute weight loss (weight
difference).
2. I am now 75% compared to my extra weight before (weight
ratio).
3. I have 25% reduction relative to my base line extra weight
(relative weight reduction).
Table 1 Hypothetical examples of different risk parameters.
Term CER EER RD RR RRR
Number of patients 40/100 30/100
Equation Event/total Event/total CER–EER EER/CER RD/CER
Proportion (%) 40 30 10 30/40 = 75 10/40 = 25
Proportion (decimal) 0.4 0.3 0.1 0.3/0.4 = 0.75 0.1/0.4 = 0.25
Odds 40/60 30/70
Proportion (%) 67% 43%
Proportion (decimal) 0.67 0.43
OR 0.43/0.67 = 0.64
CER= control event rate, EER= experimental event rate, RD= risk difference, RR = risk ratio, RRR= relative risk reduction,
OR= odds ratio. Odds = event/non-event.
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express this decrease risk of outcome as shown in Table 1.
2. Event Rate (ER)
The simplest measure of association to understand is the risk
(or absolute risk). We often refer to the risk of the adverse out-
come in the control group as the baseline risk or the control
event rate (CER). When you apply intervention that changes
the risk to a new event rate it called experimental event rate
(EER). In our example, the risk of death with diet is
CER= 40/100 = 0.4 or 40% while the risk of death with gas-
tric band EER= 30/100 = 0.3 or 30%
ER ¼ number of events=total number of the group ð1Þ3. Risk Difference (RD)
One way of comparing two risks is by calculating the absolute
difference between them. We refer to this as risk difference
(RD) or as the absolute risk reduction (ARR). The formula
for calculating the RD is:
RD ¼ jER EERj ð2Þ
The symbol | | was used to indicate that this parameter uses
absolute rather than relative terms in looking at the proportion
of patients who are spared from the adverse outcome.
In our example, the RD is 0.4  0.0.3 = 0.1. That means a
RD of 10%. In this case there is a reduction of 10% which is
also called absolute risk reduction (ARR).
Let us assume that the intervention (gastric band surgery)
caused increase in mortality and made it 60% (the base line
was 40%).
In this case RD= |CER  EER| = |0.4  0.6| = |0.2| =
20% increase in risk or what is called absolute risk increase
(ARI).
It might be easier for clinicians to avoid the terms ARR and
ARI and only stick to RD as it will be able to express both
conditions.
4. Risk Ratio (RR)
Another way to compare the risks in the two groups is to
take the current risk (EER) in ratio to the base line risk
(CER). The RR tells us the proportion of the original risk(in this case, the risk of death with overweight) that is still
present when patients receive the experimental treatment (in
this case, gastric band). That is why it is sometimes called rel-
ative risk or risk remaining (RR). From Table 1 the formula
of its calculation is
RR ¼ EER=CER ð3Þ
In our example, the RR of dying after receiving gastric
band operation vs. after diet control is calculated by having
30/100 (the risk in the gastric band group) divided by 40/100
(the risk in the diet group), or 0.75. In everyday English, we
would say the risk of death with gastric band is about three-
quarters that with diet.
5. The relative risk reduction (RRR)
An alternative relative measure of treatment effectiveness is the
relative risk reduction (RRR), an estimate of the proportion of
baseline risk that is removed by the intervention. It may be cal-
culated by dividing the RD (amount of risk removed) by the
risk in the control group One can also calculates the RRR as
1  RR (see Table 1)
RRR ¼ RD=CER or RRR ¼ 1RR ð4Þ
In our example, where RR was 0.75, the RRR is thus
1  0.75. Alternatively it can be calculated by having 10%
(the risk difference) divided by 40% (the risk in the diet group).
Either way, it comes to 0.25 or 25%. In other words, gastric
band decreases the risk of death by about a quarter compared
with diet.
6. Relative risk vs. risk difference
Failing to distinguish between the RD and the RR when
interpreting randomized trial results can be a source of mis-
understanding and misinterpretation. The reason is that the
RR is generally far larger than the RD, and presentations
of results in the form of RR (or RRR) can convey a mislead-
ing message.
Consider a treatment that is administered to three different
subpopulations of patients and which, in each case, decreases
the risk by 1/3 (RRR, 0.33; RR, 0.67). When administered
to a subpopulation with a 30% risk of dying, treatment re-
duces the risk to 20%. When administered to a population
with a 10% risk of dying, treatment reduces the risk to
6.7%. In the third population, treatment reduces the risk of
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that appears as 33% relative risk reduction.Figure 1 Normogram for calculating the number needed to treat
(Chatellier et al., 1996).7. The number needed to treat
When applying an intervention with proven beneﬁt, not all the
intervention group will have the good outcome but rather
number of patients in the intervention group will have the
good outcome (more than the control). The question now is
how many patient in the intervention group you need to treat
so as one patient will have a better outcome more than the con-
trol. It can be also expressed by the number of patients one
would need to treat to prevent one adverse event more than
the control. Table 1 shows that the risk of dying in the gastric
band group is 30%; and in the diet group, it is 40%, an RD of
10%. If treating 100 patients results in avoiding 10 events, how
many patients do we need to treat to avoid 1 event? The an-
swer, 100 divided by 10 = 10 which is the NNT. If treating
100 patients results in avoiding 20 events, how many patients
do we need to treat to avoid 1 event? The answer, 100 divided
by 20 = 5. The smaller the NNT the more effective is the
intervention.
NNT ¼ 100=RD ð5Þ
Given knowledge of the baseline risk and RRR, a nomo-
gram presents another way of arriving at the NNT (see
Fig. 1).
Assuming a constant RRR, the NNT is inversely related to
the proportion of patients in the control group who have an
adverse event. If the risk of an adverse event doubles for exam-
ple (if we deal with patients at a higher risk of death than those
included in the clinical trial), we need to treat only half as
many patients to prevent an adverse event; if the base line risk
decreases by a factor of 4 (patients are younger, have less
comorbidity than those in the study), we will have to treat 4
times as many people. The NNT is also inversely related to
the RRR. With the same baseline risk, a more effective treat-
ment with twice the RRR will reduce the NNT by half. If
the RRR with 1 treatment is only a quarter of that achieved
by an alternative strategy, the NNT will be 4 times greater
(Guyatt et al., 2008).8. The number needed to harm (NNH)
Clinicians can calculate the number needed to harm (NNH) in a
similar way. If you expect 5 of 100 patients to become fatigued
when taking B-blocker for a year, you will have to treat 20 pa-
tients to cause 1 to become tired; and the NNH is 20.9. The likelihood of help vs. harm (LHH)
In applying the result of RCT to an individual patient, we need
to consider:
 Our patient’s risk, relative to patients in the trial, of the
event we hope to prevent with the treatment: ‘‘ft’’.
 Our patient’s risk, relative to patients in the trial, of the
side-effect we might cause from the treatment: ‘‘fh’’.
 Our patient’s perception of the severity of the event we’re
trying to prevent relative to the side-effect we might cause:
‘‘s’’.LHH ¼ ð1=NNTÞ  ft  s divided byð1=NNHÞ  fh ð6Þ
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of 9 and an NNH of 12 and we think our patient is at just half
the risk of the event but at twice the risk of the side-effect, then
the ‘‘raw’’ LHH before we adjust it for our patient’s perception
of relative severity is 1/9 · 0.5 vs. 1/12 · 2 = 1/18 vs. 1/6, or
three times as likely to harm vs. help the patient. However, if
our patient regards the severity of the event that the treatment
might prevent to be six times worse than the side-effect it might
cause, then the ﬁnal LHH= 1/18 · 6 vs. 1/6, or two times as
likely to help vs. harm (Guyatt et al., 2008).
10. The odds ratio (OR)
Instead of looking at the risk of an event which is the ratio of
events/total (ER – see Eq. (1)) one could do an estimate of hav-
ing event/ not having an event (odds).
In ordinary life one might be most familiar with odds in
the context of sporting events, when bookmakers or newspa-
per commentators quote the odds for and against a horse, a
boxer, or a tennis player winning a particular event. In the
context of games, suppose you have a dice that has 6 faces.
What is the likelihood of getting the face that has 4 dots
vs. getting some other faces on a single throw? What are
the odds of that particular event occurring vs. not occurring?
Is it 1:5 or 1:6?
The correct answer to this question is 1:5, because this ques-
tion is related to the ﬁrst probability of these two following
probabilities:
Probability 1: representing the ratio of probability that the
event (having the face of 4 dots) will happen relative to the
probability that it will not happen (i.e., having one of the other
possible 5 faces). This is ODDS In 100 patients, if 20 died then
the event rate = 20/100 = 0.2 or 20% while the odds = 20/
80 = 0.25 or 25%.
As clinicians, we are interested in the odds of experiencing
an outcome vs. avoiding that outcome. The OR represents an
alternative to explain the intervention effect: instead of looking
at the rate of an event, we could estimate the odds of having vs.
not having an event.
When used in medicine, the odds represent the number of
patients in a given group with an event divided by numberTable 2 Odds ratio at different treatment effects.
Total Death Survive Odds
Condition A: intervention is useless
Experiment 200 100 100 1:1
Control 200 100 100 1:1
OR= 1:1 / 1:1 = 1 OR= 1 no diﬀerence
Condition B: intervention is beneﬁcial
Experiment 200 50 150 1:3
Control 200 100 100 1:1
OR= 1:3 / 1:1 = 0.3 OR< 1 event less in
the treatment arm
Condition C: intervention is harmful
Experiment 200 150 50 3:1
Control 200 100 100 1:1
OR= 3:1 / 1:1 = 3 OR> 1 event more in
the treatment armof patients in the same group without it. The ratio of odds
in one group to the odds in the other group is the OR. So,
OR is a ratio of 2 ratios. Further, we are interested in those
odds in patients exposed to treatment vs. those not exposed.
When we compare odds from treated and untreated groups,
we will end up with the ratio of 2 odds, not surprisingly called
odds ratio (OR) (Guyatt et al., 2008)
Odds ¼ number of patients with events=
number of patients without events ðin the same groupÞ
ð7Þ
OR ¼ odds of experimental group=odds of control group
ð8Þ
Three conditions of OR are showing in Table 2A–C.
10.1. Odds versus risks
One can convert the odds to risk rate (event rate) or the reverse
by these equations:
Risk ðERÞ ¼ Odds=1þOdds ð9Þ
Odds ¼ ER=1 ER ð10Þ
RR ¼ OR=½1þ CERðOR 1Þ ð11Þ
For instance, if the odds of a poor surgical outcome is 0.5
(or 1:2), the risk rate is [0.5/(0.5 + 1)], or 0.33. To convert
from risks (event rate) to odds, divide risk rate by (1  risk
rate).
This relation is demonstrated in Table 1.
From Eqs. (10) and (11), if the event rate is low, one may
interpret the odds ratio (OR) as equivalent to the RR. While
the greater the magnitude of the risk rate, the greater the nu-
meric difference between the risk rate and odds. For low event
rates, common in most randomized trials, the OR and RR are
numerically very close. The RR and OR will also be closer to-
gether when the magnitude of the treatment effect is small
(that is, OR and RR are close to 1.0) than when the treatment
effect is large. With both low event rates (in which OR is
numerically close to RR) and with higher event rates (in which
they may be farther apart), the OR will always make a treat-
ment appear more effective than RR (i.e., for the same results,
the OR will be farther from 1.0 than the RR). With low event
rates, this tendency is minimal; with higher event rates, it is
more pronounced. In most instances in medical investigation,
when odds and risks are approximately equal, this is not a
problem. The exception is when event rates are very high like
if more than 40% of control patients experience myocardial
infarction or death, for instance. When odds and risks are
widely divergent, this practice will be misleading. (Guyatt
et al., 2008).11. Substitution of odds ratio with NNT or NNH
The calculation of number needed to treat (NNT) and number
needed to harm (NNH) provides another problem when inves-
tigators report ORs instead of RRs. As we stated before, the
best way of dealing with this situation when event rates are
low is to assume that the RR will be very close to the OR.
The higher the risk, the less secure the assumption. Eqs. (12)
and (13) provide a guide for making an accurate estimate of
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risk and the investigator has provided only an OR (Guyatt
et al., 2008)
NNT ¼ ½1 CERð1ORÞ=½CERð1 CERÞð1ORÞ
ð12Þ
NNH ¼ ½CERðOR 1Þ þ 1=½CERðOR 1Þð1 CERÞ
ð13Þ11.1. OR not RR in case-control studies
For randomized trials and prospective cohort studies, we can
calculate risks, odds, risk difference, RRs, ORs, and even odds
reductions.
In case-control studies, investigators choose or sample par-
ticipants not according to whether they have been exposed to
the treatment or risk factor, but according to whether they
have experienced a target outcome. Participants start the
study with or without the event, rather than with or without
the exposure or intervention. Investigators compare patients
with the adverse outcome, be it stroke, myocardial infarction,
or cancer, with controls that have not had the outcome. In
this case using RR will be a mistake and only OR can be
used. Apparent prevalence in case-control studies depends
on the ratio of sampling cases to controls, which is deter-
mined by the investigator. Effect measure that is unaltered
by prevalence required, OR only appropriate measure (Guy-
att et al., 2008).
11.2. Merits of the odds ratio (OR)
1. OR is appropriate in case-control studies when the RR
cannot be calculated because the incidence is not deter-
mined by the study or when disease prevalence is not
known.
2. May be desirable if we are performing a meta-analysis in
trials with greatly different event rates.
3. If we reverse the outcomes in the analysis and look at good
outcome (survival) rather than bad outcome (mortality),
the latter relationship will have a reciprocal OR (not true
of relative risk [RR]).
4. If we need to make adjustments for confounding factors
using multiple regression.
5. When we are measuring event rates the correct approach is
to use logistic regression models which work in terms of
odds, and report effects as odds ratios.
6. Has been the predominant measure of association because
the OR has a statistical advantage in that it is essentially
independent of the arbitrary choice between a comparison
of the risks of an event (such as death) or the corresponding
‘‘nonevent’’ (such as survival), which is not necessarily true
of the RR.
7. OR can always take values between zero and inﬁnity which
is not the case for RR.
8. OR appropriate whatever the baseline event rate (RR
becomes problematic if high event rates; for example, if
risk >0.5, we cannot have RR> 2). In some risk out-
come that can not be doubled, RR will be a problem
while OR is not. To explain take a theoretical example
of on average 51 boys are born in every 100 births.The odds of any randomly chosen delivery being that
of a boys is: number of boys 51/number of girls 49. So
odds about 1.04. The risk (or probability) of having a
boy is 51/100, or 0.51. If with exposure to factor X the
risk had doubled (RR = 2) or halved (RR= 0.5). if
the baseline risk of having a boy is 0.51 it is impossible
to double it in term of RR (>100% boys). You can still
express (and double it) by OR (double of 1.04 = 2.08)
(Guyatt et al., 2008).
11.3. Which risk measure to use?
Reducing a patient’s risk by 50% sounds impressive. That
may, however, represent a reduction in risk from 2% to
1%. The corresponding 1% RD sounds considerably less
impressive. We may get a data showing a treatment reduces
the risk of dying by a third in each population, this piece
of information is not adequate to fully capture the impact
of treatment. What if the treatment under consideration is a
potent thrombolytic therapy in which 10% of those treated
experience cerebral hemorrhage as an adverse effects? Under
these circumstances, we would probably not recommend the
treatment to most patients in the lowest base line risk group,
whose RD is only 0.3%. We would certainly explain the ben-
eﬁts and risks of treatment to the intermediate population,
those with an absolute reduction in risk of death of about
3%. In the highest risk population with an absolute beneﬁt
of 10%, we could conﬁdently recommend the treatment to
most patients. The RRR in the light of your patient’s baseline
risk. For instance, you might expect an RRR of approxi-
mately 30% in vascular events in patients with possible car-
diovascular disease with administration of statins. You
would view this RRR differently in a 40-year-old female nor-
motensive nondiabetic nonsmoker with a mildly elevated
LDL (low-density lipoprotein) (5-year risk of a cardiovascu-
lar event of approximately 2%, ARR of about 0.7%) and a
70-year-old hypertensive diabetic smoker (5-year risk of
30%, ARR of 10%). All this assumes a constant RRR across
risk groups; fortunately, a more or less constant RRR is usu-
ally the case, and we suggest you make that assumption un-
less there is evidence that suggests it is incorrect (Guyatt
et al., 2008).
The same results, if presented in different ways, may lead to
different treatment decisions (Forrow et al., 1992; Naylor
et al., 1992; Hux et al., 1994; Redelmeier and Tversky, 1990;
Bobbio et al., 1994). For example, (Forrow et al., 1992) dem-
onstrated that clinicians were less inclined to treat patients
after presentation of trial results as the absolute change in
the outcome compared with the relative change in the out-
come. In a similar study, Naylor et al. (1992) found that clini-
cians rated the effectiveness of an intervention lower when
events were presented in absolute terms rather than using
RRR. Moreover, clinicians offered lower effectiveness ratings
when they viewed results expressed in terms of NNT than
when they saw the same data as RRRs or ARRs. The pharma-
ceutic industry’s awareness of this phenomenon may be
responsible for their propensity to present physicians with
treatment-associated RRRs (Guyatt et al., 2008).
Patients are as susceptible as clinicians to how results are
communicated (Guyatt et al., 2008; Malenka et al., 1993;
McNeil et al., 1982; Hux et al., 1994). In one study, when
164 M. Elbarbaryresearchers presented patients with a hypothetical scenario of
life-threatening illness, the patients were more likely to choose
a treatment described in terms of RRR than in terms of the
corresponding ARR (Malenka et al., 1993).
12. Conclusion
From EBM perspectives, clinicians should not evaluate the
treatment effect on certain outcome risk based on RR or
RRR without clear information about patient’s baseline risk.
The RD and the NNT, in an individual patient, will be the
most useful in guiding the treatment decision. OR despite
being harder to understand is more appropriate than RR in
many situations particularly in case-controlled studies. For
conveying the information to the patient, clinicians should de-
fer from using percentages or fractions but rather should ex-
press the information to the patient in its natural frequencies.
References
Bobbio, M., Demichelis, B., Giustetto, G., 1994. Completeness of
reporting trial results: effect on physicians’ willingness to prescribe.
Lancet 343 (8907), 1209–1211.Chatellier, G., Zapletal, E., Lemaitre, D., Menard, J., Degoulet, P.,
1996. The number needed to treat: a clinically useful nomogram in
its proper context. BMJ 312 (7028), 426–429.
Forrow, L., Taylor, W.C., Arnold, R.M., 1992. Absolutely relative:
how research results are summarized can affect treatment decisions.
Am. J. Med. 92 (2), 121–124.
Guyatt, G. et al., 2008. Users’ Guides to the Medical Literature: A
Manual for Evidence-Based Clinical Practice, Preface Page, second
ed. McGraw-Hill, New York, ISBN 978-0-07-159036-5; MHID 0-
07-159036-6.
Hux, J.E., Levinton, C.M., Naylor, C.D., 1994. Prescribing propen-
sity: inﬂuence of life-expectancy gains and drug costs. J. Gen.
Intern. Med. 9 (4), 195–201.
Malenka, D.J., Baron, J.A., Johansen, S., Wahrenberger, J.W., Ross,
J.M., 1993. The framing effect of relative and absolute risk. J. Gen.
Intern. Med. 8 (10), 543–548.
McNeil, B.J., Pauker, S.G., Sox Jr., H.C., Tversky, A., 1982. On the
elicitation of preferences for alternative therapies. New Engl. J.
Med. 306 (21), 1259–1262.
Naylor, C.D., Chen, E., Strauss, B., 1992. Measured enthusiasm: does
the method of reporting trial results alter perceptions of therapeutic
effectiveness? Ann. Intern. Med. 117 (11), 916–921.
Redelmeier, D.A., Tversky, A., 1990. Discrepancy between medical
decisions for individual patients and for groups. New Engl. J. Med.
322 (16), 1162–1164.
